Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
23.02
-1.33 (-5.46%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Denali Therapeutics Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Denali Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $34.31. The average 1-year stock price forecast is 49.04% higher than the current stock price, while the lowest is $25 (+8.60%) and the highest is $42 (+82.45%).
Price Target: $34.31 (+49.04%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Denali Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 17 | 17 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 19 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $35 → $36 | Buy | Maintains | $35 → $36 | +56.39% | Jul 23, 2026 |
Unknown Analyst Goldman Sachs No rating | Goldman Sachs | Buy Maintains $41 | Buy | Maintains | $41 | +78.11% | Jul 21, 2026 |
| Deutsche Bank | Deutsche Bank | Buy Reiterates $31 → $35 | Buy | Reiterates | $31 → $35 | +52.04% | Jul 16, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $31 | Buy | Reiterates | $31 | +34.67% | Jul 15, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $40 | Buy | Maintains | $40 | +73.76% | Jul 13, 2026 |
Financial Forecast
Revenue This Year
33.97M
Revenue Next Year
103.65M
from 33.97M
Increased by 205.14%
EPS This Year
-2.37
from -2.97
EPS Next Year
-2.53
from -2.37
EPS and Forward PE are based on non-GAAP adjusted numbers.